Opendata, web and dolomites

GUT-SEQ SIGNED

Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GUT-SEQ project word cloud

Explore the words cloud of the GUT-SEQ project. It provides you a very rough idea of what is the project "GUT-SEQ" about.

assessments    treatment    am    2011    revealing    disease    materials    ibd    combines    beneficial    position    mucosal    immune    largely    golden    treatments    transformation    bowel    roles    single    mechanisms    play    parallels    inflammation    2016    critical    unexplored    resident    drug    clinical    opportunity    inflammatory    feasible    unprecedented    sequencing    strategies    adaptive    patient    samples    2012    therapy    perform    patients    dissection    complementarity    lymphocyte    tissue    characterization    cell    provides    immunity    made    fraction    burden    lymphocytes    contributions    compartments    diseases    lacking    longitudinal    seminal    pressing    building    rationale    global    discovery    nat    biological    reveal    constitutes    ilcs    responders    immunol    health    acting    concert    performing    conventional    molecular    2013    hampering    intestinal    summary    rna    unfold    immunological    personalize    network    redundancy    equivalents    innate    therapies    cells    human    signatures    unveil    lymphoid    antigen   

Project "GUT-SEQ" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-07-01   to  2025-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙500˙000.00

Map

 Project objective

Inflammatory bowel disease (IBD) constitutes an increasing global health burden, yet effective treatments are lacking. Hampering rationale treatment strategies, the human intestinal immune system remains largely unexplored. I have made seminal contributions to the discovery and characterization of innate lymphoid cells (ILCs) (Nat Immunol 2011, 2013 and 2016, Immunity 2012), revealing that in addition to antigen-specific adaptive T cells, innate equivalents play important roles in mucosal immunity. Determining the complementarity and redundancy of these two lymphocyte systems, acting in concert, is important for our understanding of inflammatory diseases and the development of novel therapies. For this proposal, I am in the beneficial position of having access to unique patient samples as well as established methods for single-cell RNA-sequencing to perform an ambitious and comprehensive molecular dissection of the human intestinal lymphocyte compartments in IBD. With this approach, I will determine parallels between known, and identify novel, subsets of tissue-resident, inflammation-associated, innate and adaptive lymphocytes. Building on this unprecedented molecular characterization, we will take on some of the most pressing clinical problems in IBD by performing longitudinal assessments of intestinal lymphocytes from IBD patients on conventional and biological treatments. As only a fraction of patients respond to treatment, this approach provides a golden opportunity to unveil immunological signatures of treatment response and “drug-induced transformation” of inflammation in non-responders. Furthermore, we will unfold critical disease mechanisms and reveal novel therapy targets and how they can be used to personalize treatment. In summary, my ambitious, yet feasible, proposal combines state-of-the-art technology with access to unique patient materials. My studies are likely to advance our understanding of the complex intestinal lymphocyte network in IBD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GUT-SEQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GUT-SEQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More